BioNTech SE - ADR vs GE Aerospace — how do they compare? BioNTech SE - ADR trades at $92.64 (market cap $23.31B), while GE Aerospace trades at $368.48 (market cap $380.47B). The key difference: GE Aerospace is far larger — about 16.3× BioNTech SE - ADR's market cap, and GE Aerospace pays a 0.51% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | GE | |
|---|---|---|
Market Cap | $23.31B | $380.47B |
Sector | Health | Industrials |
52-Week High | $119.34 | $381.22 |
52-Week Low | $83.89 | $265.93 |
Enterprise Value | $6.60B | $390.29B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
GE Aerospace (GE) trades at $368.06, down 0.55% with a bullish technical signal supported by strong earnings beats and robust order growth. The company shows impressive profitability with 48.79% ROE and 17.72% net margin, though valuation metrics appear elevated with a P/E of 43.24. Recent defense contract wins and commercial engine demand fuel positive sentiment, with analysts maintaining strong buy consensus.
GE presents growth potential through aerospace expansion and defense contracts, but faces risks from high debt levels and rich valuations. The $414.11 price target suggests 12.5% upside, supported by consistent earnings outperformance and strategic investments in manufacturing capacity.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →